Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active
Timothy S. Pardee(Atrium Health Wake Forest Baptist), Bayard L. Powell(Atrium Health Wake Forest Baptist), Susan Lyerly(Atrium Health Wake Forest Baptist), Leslie R. Ellis(Atrium Health Wake Forest Baptist), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Kris C. Wood(Duke University), Sarah Dralle(Atrium Health Wake Forest Baptist), Mariaelena Pierobon(George Mason University), Kevin Lin(The University of Texas MD Anderson Cancer Center), Dianna S. Howard(Atrium Health Wake Forest Baptist), Megan Manuel(Atrium Health Wake Forest Baptist), Justine C. Rutter(Duke University), Rupali Bhave(Atrium Health Wake Forest Baptist)
Cited by 3
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation
|Journal of Clinical Investigation|2014|717
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
|The Lancet Oncology|2020|541
Controlling interlayer diffusion to achieve sustained, multiagent delivery from layer-by-layer thin films
|Proceedings of the National Academy of Sciences|2006|270